CARIN Trial design: Patients undergoing coronary angiography were randomized in a 1:1:1:1 fashion to CMX-2043 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg, or placebo. Patient follow-up was 90 days. Results (p > 0.05) Primary outcome, acute kidney injury (AKI) at 4 days for CMX-2043 2.4 mg/kg vs. 3.6 mg/kg vs. 4.8 mg/kg vs. placebo: 25.6% vs. 25.3% vs. 18.9% vs. 18.6%, p > 0.05 Mean eGFR at 90 days (ml/min): 42.7 vs. 45.8 vs. 43.8 vs. 44.6, p > 0.05; dialysis: 1.2% vs. 1.1% vs. 0% vs. 1.1%, p > 0.05 MACE: 2.4% vs. 11.1% vs. 3.8% vs. 4.5%, p > 0.05 100 % 50 Conclusions CMX-2043, a potent version of alpha-lipoic acid, at 3 different doses was not more efficacious than placebo in reducing AKI following coronary angiography/PCI There were also no differences in periprocedural MI or other CV outcomes Primary endpoint CMX-2043 2.4 mg/kg (n = 87) CMX-2043 3.6 mg/kg (n = 94) CMX-2043 4.8 mg/kg (n = 87) Placebo (n = 93) Presented by Dr. Deepak L. Bhatt at ACC 2016